News & Updates
Filter by Specialty:
How does IV edaravone fare for ALS in the real world?
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
How does IV edaravone fare for ALS in the real world?
10 May 2022
AChEIs and memantine cost-effective, offer improvements in AD
A systematic review and meta-analysis of Alzheimer’s disease (AD) therapies’ cost-effectiveness carried out by researchers from the Chinese University of Hong Kong (CUHK) identifies acetylcholinesterase inhibitors (AChEIs) and memantine as cost-effective and offering improvements in dementia-related symptoms.
AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022
Platelet function a potential biomarker of Alzheimer’s disease
A higher platelet response in middle-aged individuals who are free of antiplatelet therapy carries an increased risk of dementia in late life, according to a cohort study with 20 years of follow up.
Platelet function a potential biomarker of Alzheimer’s disease
07 May 2022
Physical activity associated with intact cognition after mild or moderate stroke
A Swedish register-based study finds that patients who engage in light or moderate physical activity are more likely to retain their cognitive function after a mild or moderate stroke vs inactive counterparts.
